Creating new drugs to fight chemotherapy-resistant triple negative breast cancer
Developing novel LOX inhibitors to target chemotherapy resistant TNBC
This study is working on new medications that can help make chemotherapy more effective for people with triple negative breast cancer by targeting a protein called lysyl oxidase, which can make tumors resistant to treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Loxigen, INC. NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11116003 on NIH RePORTER |
What this research studies
This research focuses on developing new inhibitors that target lysyl oxidase (LOX), a protein linked to chemotherapy resistance in triple negative breast cancer (TNBC). The project aims to create effective and safe LOX inhibitors that can help re-sensitize aggressive breast tumors to chemotherapy treatments. By using advanced screening techniques, the researchers will identify compounds that specifically engage LOX and have favorable properties for oral administration. This approach seeks to improve treatment outcomes for patients who currently have limited options due to resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have experienced resistance to conventional chemotherapy.
Not a fit: Patients with non-breast cancer types or those who have not undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with chemotherapy-resistant triple negative breast cancer.
How similar studies have performed: Previous research has shown promise in targeting LOX for overcoming chemotherapy resistance, indicating that this approach has potential based on earlier findings.
Where this research is happening
Charleston, United States
- Loxigen, INC. — Charleston, United States (Active)
Researchers
- Principal investigator: Sahin, Ozgur — Loxigen, INC.
- Study coordinator: Sahin, Ozgur
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.